PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsNicotine
Nicotine
Habitrol, Nicoderm Cq, Nicotine, Nicotrol (nicotine) is a small molecule pharmaceutical. Nicotine was first approved as Nicotrol on 1996-03-22. It is used to treat tobacco use disorder and ulcerative colitis in the USA. It is known to target transient receptor potential cation channel subfamily A member 1, P2Y purinoceptor 11, hydroxycarboxylic acid receptor 1, neuronal acetylcholine receptor subunit alpha-4, hydroxycarboxylic acid receptor 2, transient receptor potential cation channel subfamily M member 2, A-type voltage-gated potassium channel KCND3, neuronal acetylcholine receptor subunit alpha-9, hydroxycarboxylic acid receptor 3, neuronal acetylcholine receptor subunit alpha-10, and neuronal acetylcholine receptor subunit alpha-3.
Download report
Favorite
Searched
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
digestive system diseasesD004066
chemically-induced disordersD064419
mental disordersD001523
Trade Name
FDA
EMA
Habitrol, Nicoderm cq, Nicotine, Nicotrol (discontinued: Nicotrol, Prostep)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nicotine
Tradename
Company
Number
Date
Products
NICODERM CQSanofiN-020165 OTC1996-08-02
3 products, RLD
HABITROLDr Reddys LaboratoriesN-020076 OTC1999-11-12
3 products, RLD, RS
NICOTROLPfizerN-020385 RX1996-03-22
1 products, RLD, RS
Show 3 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
amazon basic care nicotine polacrilexANDA2024-05-16
aroamas cot nicotine transdermal patchesC2002632024-09-01
basic care nicotineANDA2024-06-12
berkley and jensen nicotineANDA2023-12-15
berkley and jensen nicotine polacrilexANDA2017-05-31
bjwc nicotineANDA2021-09-02
blipANDA2023-05-02
care one nicotineANDA2023-10-20
careone mini nicotine polacrilexANDA2023-10-25
careone nicotineANDA2024-03-21
Show 87 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
ulcerative colitisEFO_0000729D003093K51
tobacco use disorder—D014029F17
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N07: Other nervous system drugs in atc
— N07B: Drugs used in addictive disorders
— N07BA: Drugs used in nicotine dependence
— N07BA01: Nicotine
HCPCS
Code
Description
S4990
Nicotine patches, legend
S4991
Nicotine patches, non-legend
Clinical
Clinical Trials
2188 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Tobacco use disorderD014029—F174—211320
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Smoking cessationD016540EFO_0004319—421—18
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNicotine
INN—
Description
(S)-nicotine is a 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum. It has a role as a phytogenic insecticide, a teratogenic agent, a neurotoxin, an anxiolytic drug, a nicotinic acetylcholine receptor agonist, a biomarker, an immunomodulator, a mitogen, a peripheral nervous system drug, a psychotropic drug, a plant metabolite and a xenobiotic. It is a conjugate base of a (S)-nicotinium(1+). It is an enantiomer of a (R)-nicotine.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN1CCC[C@H]1c1cccnc1
Identifiers
PDB—
CAS-ID54-11-5
RxCUI—
ChEMBL IDCHEMBL3
ChEBI ID17688
PubChem CID89594
DrugBankDB00184
UNII ID—
Target
Agency Approved
No data
Alternate
KCND3
KCND3
Organism
Homo sapiens
Gene name
KCND3
Gene synonyms
NCBI Gene ID
3752
Protein name
potassium voltage-gated channel subfamily D member 3
Protein synonyms
potassium channel, voltage gated Shal related subfamily D, member 3, potassium ionic channel Kv4.3, potassium voltage-gated channel long, potassium voltage-gated channel, Shal-related subfamily, member 3, sha1-related potassium channel Kv4.3, voltage-gated K+ channel, Voltage-gated potassium channel subunit Kv4.3
Uniprot ID
Q9UK17
Mouse ortholog
Kcnd3 (56543)
potassium voltage-gated channel subfamily D member 3 (Q9Z0V1)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Nicotine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 42,372 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
47,261 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use